Arrowhead Pharmaceuticals (ARWR) Short-term Investments (2011 - 2026)

Arrowhead Pharmaceuticals' Short-term Investments history runs 16 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• Quarterly Short-term Investments rose 75.01% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 75.01% YoY) and the FY2025 annual result came in at $692.8 million, up 19.81% from the prior year.
• Short-term Investments was $1.6 billion for Q1 2026 at Arrowhead Pharmaceuticals, up from $715.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $1.6 billion in Q1 2026 and bottomed at $122.6 million in Q1 2022.
• A 5-year average of $523.3 million and a median of $381.3 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments soared 333.48% — and 2023, when it plunged 45.89%.
• Arrowhead Pharmaceuticals' Short-term Investments stood at $299.6 million in 2022, then slumped by 45.89% to $162.1 million in 2023, then soared by 207.83% to $499.0 million in 2024, then soared by 43.28% to $715.0 million in 2025, then jumped by 123.17% to $1.6 billion in 2026.
• Business Quant data shows ARWR's Short-term Investments at $1.6 billion in Q1 2026, $715.0 million in Q4 2025, and $692.8 million in Q3 2025.